Table 2. Platelet function disorder subgroups (described in Adler et al ¹⁶ ) .

Disorder	Possible PFD ( n  = 64)	Confirmed PFD ( n  = 54)
	Numbers (%)
Glanzmann's thrombasthenia a	0	4 (7.4)
Gi-like defects b	20 (31.3)	18 (33.3)
TxA2 pathway defects c	13 (20.3)	1 (1.9)
Collagen receptor defects d	6 (9.4)	2 (3.7)
Dense granule disorders e	1 (1.6)	4 (7.4)
α-granule disorders f	1 (1.6)	5 (9.3)
Diminished procoagulant COAT platelets g	3 (4.7)	7 (13.0)
Complex disorders h	20 (31.3)	13 (24.1)

Abbreviations: ADP, adenosine diphosphate; PFD, platelet function disorders; TxA2, thromboxane A2. PFD subgroups were defined as follows.

^a Defect in GPIIb/IIIa associated with a severely diminished aggregation of all agonists except ristocetin, reduced expression of GPIIb/IIIa, and/or markedly reduced activation of PAC1-binding. ^{1 3 4 26}

^b Accentuated deficiency in aggregation to the Gi-coupled receptor antagonists ADP and adrenaline, associated with corresponding flow cytometry results. ^{1 3 26}

^c Absent aggregation in response to arachidonic acid, and possibly associated with an impaired response to other agonists. ^{1 3 4 24 26}

^d Isolated reduction in aggregation and secretion after stimulation with collagen and convulxin. ^{1 21 26}

^e Defect in storage and/or secretion of mepacrine. ^{1 3 4 21 26}

^f Reduced expression and/or secretion of P-selectin, associated with varying impaired aggregation after stimulation with collagen and epinephrine. ^{1 21}

^g Impaired binding of Annexin-V after incubation with convulxin and thrombin. ²¹

^hDefects in a number of agonists (LTA) and/or several flow cytometry results that cannot be attributed to any of the disorders mentioned above.